Key Highlights
- Shares of Definium Therapeutics (DFTX) surged approximately 20% following successful Phase 3 Panorama trial results for DT120 ODT in treating generalized anxiety disorder.
- The 100µg dose of DT120 ODT achieved a 9.8-point reduction in HAM-A scores compared to a 4.7-point decrease in the placebo group after 12 weeks.
- DT120 ODT has now delivered positive results in three separate Phase 3 trials, including two for anxiety disorders and one for depression.
- Treatment discontinuation rates showed minimal difference between active treatment and placebo groups (10.4% versus 10.3%), indicating favorable tolerability.
- The company anticipates submitting a New Drug Application to the FDA during the first half of 2027, following a pre-NDA consultation in Q4 2026.
Definium Therapeutics (DFTX) shares rocketed nearly 20% during Monday’s premarket session following the biotechnology company’s announcement of successful topline data from the Phase 3 Panorama clinical trial evaluating DT120 ODT as a treatment for generalized anxiety disorder (GAD).
The biotech’s shares have approximately tripled year-to-date, reflecting mounting enthusiasm from both regulators and investors regarding psychedelic-derived therapeutic approaches.
In the Panorama trial, researchers achieved the primary efficacy endpoint along with all significant secondary measures. Participants receiving a single 100-microgram administration of DT120 ODT experienced a 9.8-point reduction on the Hamilton Anxiety Rating Scale (HAM-A) at the 12-week mark. In contrast, those receiving placebo showed only a 4.7-point improvement.
The placebo-adjusted treatment difference reached 5.1 points, corresponding to an effect size of 0.64.
Particularly noteworthy was the rapid onset of therapeutic benefit. Measurable efficacy differences emerged as soon as Day 2 following treatment and persisted consistently throughout the entire study duration.
Trilogy of Successful Phase 3 Outcomes
Panorama represents the third successful Phase 3 trial for DT120 ODT in Definium’s clinical development program. The company previously disclosed positive results from the Voyage trial in GAD last August, followed by encouraging data from the Emerge study in major depressive disorder announced in June.
Chief Executive Officer Robert Barrow emphasized that securing two positive GAD trials provides crucial evidence regarding the mechanism underlying the drug’s therapeutic effects—a critical consideration for regulatory authorities. He highlighted that approximately twelve development programs have unsuccessfully pursued FDA approval for GAD treatments over the past two decades.
Generalized anxiety disorder impacts approximately 26 million adults across the United States and is conventionally treated through combinations of antidepressant medications, anxiolytics, and various forms of psychotherapy.
The Panorama study enrolled 245 patients and incorporated a 50-microgram dose cohort designed to mitigate functional unblinding risks—where participants deduce their treatment assignment based on distinctive drug effects. Despite this precaution, patients receiving either dose demonstrated ability to accurately identify whether they received active treatment versus placebo.
According to Barrow, the superior efficacy demonstrated by the 100-microgram dose relative to the 50-microgram arm simplifies regulatory discussions moving forward.
Safety Profile and Regulatory Pathway
Safety outcomes aligned with previously reported data from earlier clinical investigations. The majority of treatment-related adverse events were classified as mild to moderate in severity, temporary in nature, and predominantly manifested on the day of drug administration.
Study discontinuation rates proved virtually identical between treatment arms: 10.4% among DT120 ODT recipients compared to 10.3% in the placebo cohort.
Throughout over 1,000 treatment sessions conducted within the Phase 3 clinical program through September 10, 2026, an impressive 97% of study participants satisfied end-of-session discharge criteria within eight hours.
Definium has scheduled a pre-NDA consultation with the FDA for the fourth quarter of 2026 and projects filing a complete New Drug Application during the first half of 2027.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
